A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients with Operable Stage I/II Non-Small Cell Lung Cancer
Principal Investigator
Robert Timmerman, MD
Status
Terminated
Date Opened To Accrual
December 18 2007
Date Closed to Accrual
May 17 2010
Date of Study Termination
May 14 2018
Disease Site
Lung [LU]
Non-small Cell Lung Cancer
Phase
II
Developmental Therapeutics
No
Primary Objective
The primary objective of the study is to determine whether radiotherapy involving high biological dose with limited treatment volume (using SBRT techniques) achieves acceptable primary tumor control (i.e., = >90% at 2 years) in operable patients with early-stage NSCLC.
Data Collection Notice:
Data for this trial is being collected via the NRG/RTOG Data Center.
Patient Population
Patients with T1, T2 (<= 5 cm), T3 (<= 5 cm), N0, M0 operable non-small cell lung cancer; patients with T3 tumors must have chest wall primary tumors only; no patients with tumors of any T-stage in the zone of the proximal bronchial tree. Patients with T3 tumors based on mediastinal invasion or < 2 cm toward carina invasion are not eligible.
Target Accrual
33
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.